Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$52.09+2.7%$52.39$35.45▼$61.69$102.76B0.363.78 million shs3.01 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+2.74%-0.31%+1.38%-4.78%+36.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$52.09+2.7%$52.39$35.45▼$61.69$102.76B0.363.78 million shs3.01 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+2.74%-0.31%+1.38%-4.78%+36.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 2.00Hold$53.001.75% UpsideCurrent Analyst Ratings BreakdownLatest GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/9/2026GSKGSK Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$43.07B2.45$6.16 per share8.45$10.32 per share5.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$7.54B$3.8513.5410.252.6217.82%44.28%11.49%7/28/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.813.47%-7.86%47.01%N/ALatest GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK0.800.790.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK66,8412.03 billion1.82 billionOptionableGSK HeadlinesRecent News About These CompaniesGSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsJune 21 at 2:10 PM | finance.yahoo.comSpero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems BewilderingJune 18, 2026 | seekingalpha.comBiogen to Strengthen Immunology Pipeline With $1B RayThera BuyoutJune 18, 2026 | zacks.comGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsJune 18, 2026 | zacks.comTraders Purchase Large Volume of GSK Put Options (NYSE:GSK)June 18, 2026 | americanbankingnews.comUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17, 2026 | finance.yahoo.comUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17, 2026 | globenewswire.comUS FDA approves GSK's oral antibiotic for drug-resistant UTIsJune 17, 2026 | reuters.comThe Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSKJune 17, 2026 | finance.yahoo.comFDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV PreventionJune 16, 2026 | zacks.comHaleon unveils new corporate identity in Nigeria after GSK demergerJune 16, 2026 | nairametrics.comNGSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Hold" from AnalystsJune 16, 2026 | americanbankingnews.comMarketBeat Week in Review – 06/08 - 06/12 (GSK)...June 13, 2026 | marketbeat.comGSK Engitix Liver Fibrosis Pact Adds Early Stage Upside For ValuationJune 12, 2026 | finance.yahoo.comGSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory DisorderJune 12, 2026 | finance.yahoo.comGSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory DisorderJune 12, 2026 | zacks.comIs GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says OvervaluedJune 11, 2026 | gurufocus.comPharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesJune 11, 2026 | zacks.comPatent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion (GSK)...June 11, 2026 | marketbeat.comGSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC TreatmentsJune 11, 2026 | genengnews.comGGSK's Bold $10.6 Billion Move: Reviving Oncology AspirationsJune 11, 2026 | devdiscourse.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026GSK Company DescriptionsGSK NYSE:GSK$52.09 +1.35 (+2.66%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$51.82 -0.27 (-0.52%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
